Ole Köhler-Forsberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/57899/publications.pdf

Version: 2024-02-01

60 papers 2,896 citations

430442 18 h-index 51 g-index

62 all docs

62 docs citations

times ranked

62

4504 citing authors

#	Article	IF	CITATIONS
1	Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects. JAMA Psychiatry, 2014, 71, 1381.	6.0	727
2	Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Current Neuropharmacology, 2016, 14, 732-742.	1.4	367
3	Efficacy of antiâ€inflammatory treatment on major depressive disorder or depressive symptoms: metaâ€analysis of clinical trials. Acta Psychiatrica Scandinavica, 2019, 139, 404-419.	2.2	257
4	Comorbid depression in medical diseases. Nature Reviews Disease Primers, 2020, 6, 69.	18.1	234
5	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	2.0	202
6	Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Molecular Psychiatry, 2019, 24, 869-887.	4.1	151
7	A Nationwide Study in Denmark of the Association Between Treated Infections and the Subsequent Risk of Treated Mental Disorders in Children and Adolescents. JAMA Psychiatry, 2019, 76, 271.	6.0	141
8	Infections and exposure to antiâ€infective agents and the risk of severe mental disorders: a nationwide study. Acta Psychiatrica Scandinavica, 2017, 135, 97-105.	2.2	88
9	Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis. Brain, Behavior, and Immunity, 2020, 90, 364-380.	2.0	66
10	Parental Infections Before, During, and After Pregnancy as Risk Factors for Mental Disorders in Childhood and Adolescence: A Nationwide Danish Study. Biological Psychiatry, 2019, 85, 317-325.	0.7	63
11	Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain and Behavior, 2015, 5, e00338.	1.0	55
12	C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression - associations with mortality and psychiatric outcomes: a population-based study. European Psychiatry, 2017, 44, 164-172.	0.1	46
13	Association of Exposure to Infections in Childhood With Risk of Eating Disorders in Adolescent Girls. JAMA Psychiatry, 2019, 76, 800.	6.0	34
14	Statin treatment and the risk of depression. Journal of Affective Disorders, 2019, 246, 706-715.	2.0	31
15	Otitis media, antibiotics, and risk of autism spectrum disorder. Autism Research, 2018, 11, 1432-1440.	2.1	26
16	Statins in the treatment of depression: Hype or hope?., 2020, 215, 107625.		26
17	Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis. European Neuropsychopharmacology, 2022, 54, 116-125.	0.3	25
18	Do Statins Have Antidepressant Effects?. CNS Drugs, 2017, 31, 335-343.	2.7	22

#	Article	IF	CITATIONS
19	Mortality in unipolar depression preceding and following chronic somatic diseases. Acta Psychiatrica Scandinavica, 2018, 138, 500-508.	2.2	22
20	Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder. JAMA Psychiatry, 2022, 79, 454.	6.0	20
21	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. Journal of Affective Disorders, 2017, 223, 146-152.	2.0	18
22	Infections of the central nervous system as a risk factor for mental disorders and cognitive impairment: A nationwide register-based study. Brain, Behavior, and Immunity, 2020, 88, 668-674.	2.0	16
23	Predictors of Nonhospitalization and Functional Response in Clozapine Treatment. Journal of Clinical Psychopharmacology, 2017, 37, 148-154.	0.7	15
24	Infections, Anti-infective Agents, and Risk of Deliberate Self-harm and Suicide in a Young Cohort: A Nationwide Study. Biological Psychiatry, 2019, 85, 744-751.	0.7	15
25	Preâ€diagnostic and postâ€diagnostic psychopharmacological treatment of 16Â288 patients with bipolar disorder. Bipolar Disorders, 2021, 23, 357-367.	1.1	15
26	Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 621-630.	1.0	13
27	Infections, antibiotic treatment and the Microbiome in relation to schizophrenia. Schizophrenia Research, 2021, 234, 71-77.	1.1	13
28	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depression and Anxiety, 2017, 34, 281-290.	2.0	12
29	Evolving Issues in the Treatment of Depression. JAMA - Journal of the American Medical Association, 2019, 321, 2401.	3.8	12
30	Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse – a population-based study of 16,253 incident patients with schizophrenia. Expert Opinion on Pharmacotherapy, 2016, 17, 1055-1062.	0.9	11
31	Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence – A Danish nationwide study. Schizophrenia Research, 2018, 199, 116-122.	1.1	10
32	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatrica, 2018, 30, 297-305.	1.0	10
33	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. British Journal of Psychiatry, 2019, 215, 494-501.	1.7	10
34	Childhood Infections and Subsequent School Achievement Among 598,553 Danish Children. Pediatric Infectious Disease Journal, 2018, 37, 731-737.	1.1	9
35	Streptococcal Infections and Exacerbations in PANDAS. Pediatric Infectious Disease Journal, 2019, 38, 189-194.	1.1	9
36	Childhood trauma and treatment outcomes during moodâ€stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. Acta Psychiatrica Scandinavica, 2022, 145, 615-627.	2.2	9

#	Article	IF	CITATIONS
37	Anti-inflammatory Intervention in Depression—Reply. JAMA Psychiatry, 2015, 72, 512.	6.0	8
38	Association between prior somatic disease and 5-year relapse risk among 11,856 incident patients with schizophrenia. European Psychiatry, 2019, 59, 1-7.	0.1	7
39	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80,	1.1	7
40	Editorial: The Role of Inflammation in the Etiology and Treatment of Schizophrenia. Frontiers in Psychiatry, 2020, 11, 603296.	1.3	7
41	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. Journal of Affective Disorders, 2020, 273, 131-137.	2.0	7
42	Association between global functioning at first schizophrenia diagnosis and treatment resistance. Microbial Biotechnology, 2018, 12, 1198-1202.	0.9	6
43	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. Journal of Affective Disorders, 2022, 300, 41-49.	2.0	6
44	White blood cell count at first depression diagnosis as predictor for risk of subsequent hospitalization with depression. Neurology Psychiatry and Brain Research, 2017, 26, 1-6.	2.0	5
45	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disorders, 2018, 21, 350-360.	1.1	5
46	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depression and Anxiety, 2021, 38, 114-123.	2.0	5
47	The effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: A propensity score matched cohort study. European Neuropsychopharmacology, 2020, 32, 120-130.	0.3	4
48	Medical diseases prior to first-time depression diagnosis and subsequent risk of admissions for depression: A nationwide study of 117,585 patients. Journal of Affective Disorders, 2020, 276, 1030-1037.	2.0	3
49	The 10-year trajectories of auditory hallucinations among 496 patients with a first schizophrenia-spectrum disorder: Findings from the OPUS cohort. Schizophrenia Research, 2021, , .	1.1	3
50	Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram. Psychological Medicine, 2021, , 1-9.	2.7	3
51	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. Australian and New Zealand Journal of Psychiatry, 2023, 57, 93-103.	1.3	3
52	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. Acta Neuropsychiatrica, 2019, 31, 230-234.	1.0	2
53	Freeâ€ofâ€charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications. Basic and Clinical Pharmacology and Toxicology, 0, , .	1.2	2
54	Efficacy of Anti-Inflammatory Treatment in Depression. , 2018, , 525-538.		1

#	Article	IF	CITATIONS
55	Metaâ€analysis of antidepressant effects of antiâ€inflammatory drugsâ€"reply. Acta Psychiatrica Scandinavica, 2019, 140, 385-386.	2.2	1
56	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. Psychiatry Research, 2021, 305, 114194.	1.7	1
57	Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study. Schizophrenia Research, 2022, 246, 268-276.	1.1	1
58	T11. CEREBROSPINAL FLUID (CSF) MARKERS OF INFLAMMATION AND INFECTIONS IN SCHIZOPHRENIA AND AFFECTIVE DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Schizophrenia Bulletin, 2018, 44, S116-S117.	2.3	0
59	Authors' reply. British Journal of Psychiatry, 2020, 216, 345-346.	1.7	0
60	Complex Interaction of Lithium With Kidney and Bone Healthâ€"Reply. JAMA Psychiatry, 0, , .	6.0	0